SPDR S&P Biotech ETF (XBI) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
SPDR S&P Biotech ETF (XBI) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How XBI Turns Every Dollar of Sales Into Real Bottom-Line Profit
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring XBI)
- ✓Live walkthrough of XBI's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
XBI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +9.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on XBI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for XBI. Explore sector supply chains on /butterfly.
XBI Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is SPDR S&P Biotech ETF (XBI)?
In Trailing 12 Months, XBI converted $4.0B of revenue into a 58% gross margin, 24% operating margin, and $251.6M in free cash flow (6.3% FCF margin).